Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Knockout T Cells in Metastatic Renal Cell Carcinoma
NCT02867332Phase 1Withdrawn
- Sponsor
- Peking University
- Start
- Nov 2016
- Primary completion
- Nov 2020
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
01
Overview
Phase 1, randomised, open-label trial of pd-1 knockout t cells in renal cell carcinoma (RCC) (2 arms), sponsored by Peking University. Primary endpoint: Number of participants with Adverse Events and/or Dose Limiting Toxicities at 6 months. Planned start Nov 2016; status: withdrawn.
02
Drugs
pd-1 knockout t cells
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02867332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867332.